{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T21:37:09Z","timestamp":1793223429748,"version":"4.5.0"},"reference-count":19,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2012,3,27]],"date-time":"2012-03-27T00:00:00Z","timestamp":1332806400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["bjui-journals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["BJU International"],"published-print":{"date-parts":[[2012,11]]},"abstract":"<jats:sec>\n                    <jats:label\/>\n                    <jats:p>Study Type \u2013 Aetiology (case control)<\/jats:p>\n                    <jats:p>Level of Evidence\u20033b<\/jats:p>\n                    <jats:p>\n                      <jats:bold>What's known on the subject? and What does the study add?<\/jats:bold>\n                    <\/jats:p>\n                    <jats:p>\n                      Recent evidence has suggested that up\u2010regulation of the prostaglandin E\n                      <jats:sub>2<\/jats:sub>\n                      (PGE\n                      <jats:sub>2<\/jats:sub>\n                      ) receptor subtype 4 (EP4) receptor in the bladder is involved in bladder overactivity.\n                    <\/jats:p>\n                    <jats:p>\n                      The present study found that MF191, a selective EP4 receptor antagonist, may have effects on the bladder urothelium and inflammatory cells and suppress CYP\u2010 or PGE\n                      <jats:sub>2<\/jats:sub>\n                      \u2010induced bladder overactivity. Systemic or intravesical MF191 administration for the treatment of overactive bladder may merit clinical study.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>OBJECTIVE<\/jats:title>\n                    <jats:p>\n                      <jats:list list-type=\"explicit-label\">\n                        <jats:list-item>\n                          <jats:p>\n                            To investigate the mechanisms and urodynamic effects of a potent and selective prostaglandin E\n                            <jats:sub>2<\/jats:sub>\n                            (PGE\n                            <jats:sub>2<\/jats:sub>\n                            ) receptor subtype 4 (EP4) antagonist, MF191, on cyclophosphamide (CYP) or PGE\n                            <jats:sub>2<\/jats:sub>\n                            \u2010induced bladder overactivity in rats.\n                          <\/jats:p>\n                        <\/jats:list-item>\n                      <\/jats:list>\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>MATERIALS AND METHODS<\/jats:title>\n                    <jats:p>\n                      <jats:list list-type=\"explicit-label\">\n                        <jats:list-item>\n                          <jats:p>Experimental and control rats were injected with CYP (200\u2003mg\/kg i.p.) or saline on day 1. Continuous cystometrogram (CMGs) were performed on day 3.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>In group 1, MF191 (vehicle 0.1 and 1\u2003mg\/kg) was given i.v. The bladder was then harvested for histology and immunohistochemistry. Some bladders were harvested for analysis of EP4 expression by Western blotting without a CMG study.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>In group 2, MF191 (vehicle 10\u2003nM, and 100\u2003nM) was continuously infused into the bladder.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>\n                            In group 3, bladder overactivity was induced by intravesical instillation of PGE\n                            <jats:sub>2<\/jats:sub>\n                            (200\u2003uM) and vehicle or MF191 (1\u2003mg\/kg) was given i.v.\n                          <\/jats:p>\n                        <\/jats:list-item>\n                      <\/jats:list>\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>\n                      <jats:list list-type=\"explicit-label\">\n                        <jats:list-item>\n                          <jats:p>CYP induced bladder inflammation, overactivity and EP4 upregulation. The CYP effects were suppressed by MF191 (1\u2003mg\/kg i.v.; intercontraction interval [ICI]: 39.4% increase, and reduced inflammatory cells infiltration, and EP4 expression).<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>Intravesical instillation of MF191 (100\u2003nM) suppressed CYP\u2010induced bladder overactivity (ICI: 71.8% increase).<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>\n                            PGE\n                            <jats:sub>2<\/jats:sub>\n                            \u2010induced bladder overactivity was suppressed by MF191 (ICI: 43.2% increase).\n                          <\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>MF191 had no significant effects on other CMG variables or on control rats.<\/jats:p>\n                        <\/jats:list-item>\n                      <\/jats:list>\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSIONS<\/jats:title>\n                    <jats:p>\n                      <jats:list list-type=\"explicit-label\">\n                        <jats:list-item>\n                          <jats:p>\n                            MF191 might affect the bladder urothelium and inflammatory cells and suppresses CYP\u2010 or PGE\n                            <jats:sub>2<\/jats:sub>\n                            \u2010induced bladder overactivity.\n                          <\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>Systemic or intravesical MF191 administration for the treatment of overactive bladder merits clinical study.<\/jats:p>\n                        <\/jats:list-item>\n                      <\/jats:list>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/j.1464-410x.2012.11096.x","type":"journal-article","created":{"date-parts":[[2012,3,27]],"date-time":"2012-03-27T08:27:11Z","timestamp":1332836831000},"page":"1558-1564","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Mechanisms and urodynamic effects of a potent and selective EP4 receptor antagonist, MF191, on cyclophosphamide and prostaglandin E\n                    <sub>2<\/sub>\n                    \u2010induced bladder overactivity in rats"],"prefix":"10.1111","volume":"110","author":[{"given":"Yao\u2010Chi","family":"Chuang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pradeep","family":"Tyagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao\u2010Cheng","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael B.","family":"Chancellor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Yoshimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2012,3,27]]},"reference":[{"key":"e_1_2_8_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2009.11.004"},{"key":"e_1_2_8_3_2","doi-asserted-by":"publisher","DOI":"10.1124\/pr.56.4.4"},{"key":"e_1_2_8_4_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2009.08705.x"},{"key":"e_1_2_8_5_2","doi-asserted-by":"publisher","DOI":"10.1002\/nau.20460"},{"key":"e_1_2_8_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2006.11.070"},{"key":"e_1_2_8_7_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00300786"},{"key":"e_1_2_8_8_2","doi-asserted-by":"publisher","DOI":"10.1002\/nau.20981"},{"key":"e_1_2_8_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(05)00992-4"},{"key":"e_1_2_8_10_2","first-page":"44","article-title":"Effects of prostaglandine (PG) E2 receptors antagonist in overactive bladder in chronic spinal rats","volume":"163","author":"Yoshida M","year":"2000","journal-title":"J Urol"},{"key":"e_1_2_8_11_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajprenal.90373.2008"},{"key":"e_1_2_8_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2008.05.007"},{"key":"e_1_2_8_13_2","first-page":"472","article-title":"The expression of prostaglandin E2 receptors (EP1, 2, 3 and 4) in the human urinary bladder epithelium of normal and bladder outlet obstruction\u2010 a novel mechanism in the afferent hyperactivity of bladder. 2008 AUA Meeting (Abstract 1318)","volume":"179","author":"Jiang Y","year":"2008","journal-title":"J Urol"},{"key":"e_1_2_8_14_2","doi-asserted-by":"publisher","DOI":"10.1021\/jm901771h"},{"key":"e_1_2_8_15_2","first-page":"131","article-title":"Further confirmation of the role of adenyl cyclase and of cAMP dependent protein kinase in primary afferent hyperalgesia","volume":"41","author":"Taiwo YO","year":"1989","journal-title":"Neuroscience"},{"key":"e_1_2_8_16_2","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.106.105569"},{"key":"e_1_2_8_17_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2010.09260.x"},{"key":"e_1_2_8_18_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-4159.2005.03050.x"},{"key":"e_1_2_8_19_2","doi-asserted-by":"publisher","DOI":"10.1186\/1744-8069-1-3"},{"key":"e_1_2_8_20_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2009.09132.x"}],"container-title":["BJU International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1464-410X.2012.11096.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1464-410X.2012.11096.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T07:57:09Z","timestamp":1761724629000},"score":1,"resource":{"primary":{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/10.1111\/j.1464-410X.2012.11096.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,3,27]]},"references-count":19,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2012,11]]}},"alternative-id":["10.1111\/j.1464-410X.2012.11096.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1464-410x.2012.11096.x","archive":["Portico"],"relation":{},"ISSN":["1464-4096","1464-410X"],"issn-type":[{"value":"1464-4096","type":"print"},{"value":"1464-410X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,3,27]]},"assertion":[{"value":"2012-03-27","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}